🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are reported in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval represents a significant shift in the treatment of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

As per results published in a major medical journal, the new drug cured the vast majority of cases of the STI. This places it at an comparable level with the existing first-line therapy, which combines two antibiotics. The study included nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have shared optimism. Having a one-pill regimen like this is seen as a "game-changer" for public health efforts. This is viewed as vital to alleviate the strain of the illness for individuals and to halt the transmission of untreatable gonorrhoea globally.